๐ฐ D News
Page 1023 - D News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from D. Real-time updates on events, politics, business and more.
January 9, 2024
Compensation: $22,880 - $24,960 (20 hours per.... Communications Manager Employment & Education classified ad of the High Country News Classified Marketplace, Paonia, CO. Browse Employment & Education classified ads and free ads. Post free Employment & Education classified ads.
January 9, 2024
Expert oncologists who treat patients with advanced RCC discuss updates from clinical trials presented during the 2023 European Society for Medical Oncology Congress that further defined the treatment paradigm in advanced RCC and gave a peek into the potential future of the disease management.
January 9, 2024
The Prince George's County Police Department (PGPD) said a man was arrested in connection to a fatal shooting that happened in late December.
January 9, 2024
Discover the latest news in cardiology.
January 9, 2024
Hillary Beall contract and salary cap details, contract breakdowns, dead money, and news.
January 9, 2024
Cinesite Immersive will focus on creative IP owners and brands; in new partnership with Frameless Creative, has collaborated on two art projects based on works by Rembrandt and Monet; watch the โMaking Ofโ featurette.
January 9, 2024
PLEASE READ ENTIRE AD, ALL FEES DUE AT TIME OF SALE ARE DISCLOSED (The Pictures In This Ad Are General In Nature)Please note that we are not affiliated with nor do we represent the resort described in | RealGeni.com
January 9, 2024
GREENBELT, Md. (DC News Now) — A social media influencer from Maryland was sentenced on Tuesday to three years in federal prison for wire fraud, identity theft and money laundering. He pled guilty to the charges on May 31, 2023. The U.S. Attorney’s Office said that 32-year-old Denish Sahadevan, also known as “Danny Devan,” of […]
January 9, 2024
Andrew Kuykendall, MD, discusses the efficacy of the combination of pelabresib and ruxolitinib in patients with JAK inhibitorโnaive myelofibrosis based on data from the phase 3 MANIFEST-2 trial.